MEI 007
Alternative Names: MEI-007Latest Information Update: 11 Jul 2025
At a glance
- Originator Nanjing Minova Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Scars
Most Recent Events
- 10 Jul 2025 Preclinical trials in Scars in China (unspecified route), before July 2025 (Nanjing Minova Pharmaceutical pipeline, July 2025)
- 10 Jul 2025 Preclinical trials in Scars in USA (unspecified route), before July 2025 (Nanjing Minova Pharmaceutical pipeline, July 2025)